NCT00563797View on ClinicalTrials.gov

Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence

PHASE3CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Alcohol DependenceDepression
Interventions
DRUG

Mecamylamine

mecamylamine 10mg/day for 12 weeks

DRUG

Placebo

Placebo pill

Trial Locations (1)

06516

VA Connecticut Healthcare System, West Haven

All Listed Sponsors
collaborator

National Alliance for Research on Schizophrenia and Depression

OTHER

lead

Yale University

OTHER

NCT00563797 - Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence | Biotech Hunter | Biotech Hunter